Healthpoint's Leg Ulcer Cell Therapy Hits Phase III Trial
Healthpoint Biotherapeutics, of Fort Worth, Texas, began a Phase III trial of its allogeneic living cell bioformulation, HP802-247, for venous leg ulcers. The study will assess wound closure with HP802-247 plus compression therapy over a period of 12 weeks.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter